Published in final edited form as:

Front Biol (Beijing). 2016 August ; 11(4): 285–304. doi:10.1007/s11515-016-1415-1.

New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins

Jian Li, Chun Guo, Nickolas Steinauer, and Jinsong Zhang[✉]

Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri 63104, USA

Abstract

BACKGROUND—Nearly 15% of acute myeloid leukemia (AML) cases are caused by aberrant expression of AML1-ETO, a fusion protein generated by the t(8;21) chromosomal translocation. Since its discovery, AML1-ETO has served as a prototype to understand how leukemia fusion proteins deregulate transcription to promote leukemogenesis. Another leukemia fusion protein, E2A-Pbx1, generated by the t(1;19) translocation, is involved in acute lymphoblastic leukemias (ALLs). While AML1-ETO and E2A-Pbx1 are structurally unrelated fusion proteins, we have recently shown that a common axis, the ETO/E-protein interaction, is involved in the regulation of both fusion proteins, underscoring the importance of studying protein–protein interactions in elucidating the mechanisms of leukemia fusion proteins.

OBJECTIVE—In this review, we aim to summarize these new developments while also providing a historic overview of the related early studies.

METHODS—A total of 218 publications were reviewed in this article, a majority of which were published after 2004. We also downloaded 3D structures of AML1-ETO domains from Protein Data Bank and provided a systematic summary of their structures.

RESULTS—By reviewing the literature, we summarized early and recent findings on AML1-ETO, including its protein–protein interactions, transcriptional and leukemogenic mechanisms, as well as the recently reported involvement of ETO family corepressors in regulating the function of E2A-Pbx1.

CONCLUSION—While the recent development in genomic and structural studies has clearly demonstrated that the fusion proteins function by directly regulating transcription, a further understanding of the underlying mechanisms, including crosstalk with other transcription factors and cofactors, and the protein–protein interactions in the context of native proteins, may be necessary for the development of highly targeted drugs for leukemia therapy.

Keywords

AML1-ETO; E2A-Pbx1; E-proteins; chromosomal translocation; transcription; leukemia

Correspondence: Jinsong Zhang, jinsongzhang@slu.edu.

Compliance with ethics guidelines

Jian Li, Chun Guo, Nickolas Steinauer and Jinsong Zhang declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

Introduction

All lineages of blood cells are differentiated from multi-potent hematopoietic stem/progenitor cells (hereinafter referred to as HSCs). HSCs have the ability to undergo self-renewal and/or differentiation into mature lineages. These mature lineages include erythrocytes, platelets, and white blood cells. The latter contain myeloid cells, megakaryocytes, and lymphocytes (B and T cells) (Seita and Weissman, 2010). HSC differentiation is controlled by master transcriptional regulators. One such regulator is RUNX1 (also called AML1, see below), a sequence-specific transcription factor required for definitive hematopoiesis in mice (Okuda et al., 1996).

While RUNX1 has an important physiological function, it is also a target of chromosomal translocations, many of which generate leukemogenic fusion proteins (Rowley, 1999). A well-studied example is the t(8;21) translocation, which fuses the RUNX1 gene at chromosome 21 to the ETO gene at chromosome 8 (Peterson and Zhang, 2004). The t(8;21) translocation is observed in 10%–15% of total AMLs and accounts for nearly 40% of the M2 subtype (Downing, 1999; Peterson and Zhang, 2004; Reikvam et al., 2011). While the first evidence of recurring t(8;21) translocation in AMLs was reported in 1973 (Rowley, 1973), it took nearly 20 years to clone the involved genes as RUNX1 (initially named AML1, acute myeloid leukemia 1) and ETO (eight twenty-one, also called MTG8, myeloid translocation gene on chromosome 8) (Miyoshi et al., 1991; Erickson et al., 1992; Miyoshi et al., 1993). The translocation occurs between intron 5 of RUNX1 and intron 1 of ETO, allowing the expression of a 752-amino acid full-length fusion protein. While the first 1–177 amino acids are derived from RUNX1, the remaining 575 amino acids are derived from ETO (Fig. 1) (Peterson and Zhang, 2004). Because transcription of wild-type ETO gene is normally silenced in hematopoietic cells, it has been proposed that an important consequence of t(8;21) translocation is expression of a high level of ETO polypeptide (Chang et al., 1993; Zhang et al., 2004).

AML1-ETO has historically served as a prototype to understand how dysregulation of transcription by leukemia fusion proteins promotes leukemogenesis. In this review, we summarize the past and recent studies, focusing on protein–protein interactions, transcriptional mechanisms, and structural characterization of RUNX1/AML1-ETO domains. A new development in the field is that in leukemia cells AML1-ETO exists as a stable complex with E-proteins including HEB and E2A. Intriguingly, while E-proteins contain three members, only E2A is involved in chromosomal translocations. One of such translocations is t(1;19), which fuses the activation domain of E2A to the DNA binding domain of Pbx1 (Fig. 1). This results in the expression of E2A-Pbx1, which interferes with pre-B cell development and leads to pre-B ALLs commonly observed in children (Mellentin et al., 1989; Kamps et al., 1990; Nourse et al., 1990; Aspland et al., 2001). A related E2A fusion protein, E2A-HLF, generated by t(17;19) translocation, is also observed in pre-B ALLs (Inaba et al., 1992). While previous studies have focused on how E2A fusion proteins interact with coactivators to drive transcriptional activation, we have shown that the fusion proteins are also subjected to negative regulation by ETO family corepressors. Enhancing corepressor interactions may be a new strategy to target E2A fusion proteins.

Transcriptional mechanisms of AML1-ETO

Early studies have supported a dominant negative model in which the AML1-ETO fusion protein competitively binds to RUNX1 target genes and interferes with RUNX1-mediated activation. However, recent studies have shown that AML1-ETO-mediated transcriptional regulation is more complex than previously thought, as evidenced by its ability to bind to other transcription factors, to recruit not only corepressors but also coactivators, and to both repress and activate transcription in a gene-specific manner. More complexity is added by the seemingly paradoxical roles of NCoR (Nuclear Receptor Co-repressor)/SMRT (Silencing Mediator for Thyroid and Retinoid Receptors, an NCoR homolog) corepressors in regulating AML1-ETO's function. While repression is considered important for AML1-ETO-mediated leukemogenesis, removal of the strong NCoR/SMRT-binding domain does not compromise but rather enhances the leukemogenic activity of AML1-ETO. In this section, we review the literature and discuss these findings.

Early studies on RUNX1 and ETO

While the t(8;21) fusion gene at chromosome 21 was initially named AML1, it is more recently referred to as RUNX1 (Runt-related transcription factor 1), reflecting its similarity to *Drosophila Runt*, including the DNA binding domain RHD (Runt-homology domain) (Erickson et al., 1992). RUNX1 is also called CBF α 2 as it requires dimerization with CBF β to bind with high affinity to enhancer core motif TGTGGT (Meyers et al., 1993; Ogawa et al., 1993; Meyers et al., 1995). RUNX1 has three splicing variants: 1a, 1b and 1c, which differ in the N-terminal and C-terminal domains (Miyoshi et al., 1995). RUNX1a uniquely lacks the C-terminal transcriptional regulatory domain, allowing it to exert antagonistic effects on RUNX1-dependent gene regulation and myeloid differentiation (Tanaka et al., 1995). RUNX1 belongs to the RUNX family of transcription factors (RUNX1–3) that share the ability to bind to the RUNX motif via dimerization with CBF β (de Bruijn and Speck, 2004; Ito, 2004). The current literature supports the notion that RUNXs have distinct biological/pathological functions, owing to their tissue/cell-specific expression patterns (Okuda et al., 1996; Zhang et al., 2000; Li et al., 2002; Lotem et al., 2015).

Cloning of ETO from t(8;21) AML immediately revealed its homology with *Drosophila* TAF110 (recently re-named as TAF4) at the N terminus and two zinc fingers at the C terminus (Erickson et al., 1994). An independent *Drosophila* screen for downstream targets of *Ultrabithorax* identified *Nervy* as the *Drosophila* homolog of ETO (Feinstein et al., 1995). Mammals possess two additional ETO-related proteins, MTGR1 (MTG8-related protein 1) (Kitabayashi et al., 1998) and ETO-2/MTG16 (myeloid translocation gene on chromosome 16) (Gamou et al., 1998). *Nervy*, ETO, MTGR1 and ETO-2 thus define a small family of evolutionarily conserved proteins. These proteins share a high degree of sequence similarity (45%–50%) at *Nervy*-Homology regions (NHR1–4) (Fig. 1). NHR1 corresponds to the aforementioned TAF4-homology domain (TAFH). NHR2 is a tetramerization domain with hydrophobic heptad repeats (HHRs) typically found in amphipathic helices (Lutterbach et al., 1998a). NHR3 displays some homology with A-kinase anchoring proteins (AKAP) (Fukuyama et al., 2001). Lastly, NHR4 is the C-terminal zinc finger domain, which is also named as MYND because of its presence in MTG8 (Myeloid translocation gene on

chromosome 8), Nery and DEAF-1 proteins (Gross and McGinnis, 1996). Underscoring the involvement of ETO family proteins in leukemias, ETO-2, like ETO, is also involved in chromosomal translocations with RUNX1, which is observed in therapy-related t(16;21)-associated AMLs (Gamou et al., 1998). While ETO expression is restricted to brain, intestine and few other tissues/cell types that exclude hematopoietic cells (Miyoshi et al., 1993; Wolford and Prochazka, 1998; Calabi et al., 2001), ETO-2 and MTGR1 appear to show broader expression patterns and are expressed in the hematopoietic compartment, including HSCs and leukemia cells (Calabi and Cilli, 1998; Fracchiolla et al., 1998; Gamou et al., 1998; Davis et al., 1999). In this regard, early reported ETO signals in CD34⁺ cells (Erickson et al., 1996) may have resulted from antibody cross-reactivity with ETO-2 and/or MTGR1, as recently confirmed by ETO knockout studies (Calabi et al., 2001).

AML1-ETO/ETO functions in repression

While ETO cannot directly bind to DNA, it harbors potent transcriptional repression domains as initially shown by Gal4-based reporter assays (Zhang et al., 2001) and, more recently, by studies showing that ETO family corepressors serve as potent transcriptional corepressors for E-proteins (Zhang et al., 2004; Guo et al., 2009; Gow et al., 2014). In the context of AML1-ETO, early indication of its repressor function was first reported in 1995 by Hiebert and colleagues. Whereas AML1b activates transcription from the T cell receptor β enhancer, co-expression with AML1-ETO inhibits the activation in a dominant negative fashion (Meyers et al., 1995). Similar inhibition was also observed for GM-CSF (Frank et al., 1995), myeloid-specific gene defensin NP-3 (Westendorf et al., 1998) and multidrug resistance 1 (MDR-1) (Lutterbach et al., 1998a). Subsequent structure-functional studies mapped the repression activity of AML1-ETO to the NHR2–4 region of ETO (Lenny et al., 1995; Lutterbach et al., 1998a). Dominant negative inhibition of RUNX1 as a leukemogenic mechanism of AML1-ETO also gains support from animal studies showing that mice carrying a knock-in AML1-ETO allele display similar defects in hematopoiesis as the RUNX1 knockout mice (Yergeau et al., 1997; Okuda et al., 1998). However, a genetic study in *Drosophila* showed that AML1-ETO can function as a constitutive repressor independent of RUNX1 (or *lozenge*, a *Drosophila* RUNX1 homolog) (Wildonger and Mann, 2005). This result shows that the ability of AML1-ETO to regulate transcription involves not only competitive binding to DNA with RUNX1, but also a more direct mechanism to repress transcription.

A major development in the field is the discovery of direct interactions of ETO with multiple transcriptional corepressors and histone deacetylases (HDACs), which links ETO-mediated repression to regulation of chromatin structure (Gelmetti et al., 1998; Lutterbach et al., 1998b; Wang et al., 1998). In these studies, reciprocal yeast-two-hybrid screens show that ETO binds to repression domain 3 (RD3) of SMRT (Gelmetti et al., 1998) and, vice versa, NCoR binds to NHR4 of ETO (Wang et al., 1998). Sin3A corepressor, a known NCoR-interacting protein, also directly interacts with ETO via NHR2 apparently through an NCoR-independent mechanism (Fig. 2) (Lutterbach et al., 1998b). These ETO-mediated corepressor/HDAC interactions are all preserved in AML1-ETO, explaining its repressive activity. In view of the reported interactions of NCoR/SMRT/Sin3A corepressors with multiple Class-I HDACs (Hassig et al., 1997; Heinzl et al., 1997; Laherty et al., 1997; Nagy

et al., 1997; Zhang et al., 1997; Guenther et al., 2000; Li et al., 2000; Zhang et al., 2002), the observed AML1-ETO/ETO-HDAC interactions may be secondary to the primary interactions with NCoR, SMRT and Sin3A (Gelmetti et al., 1998). Recently reported genome-wide chromatin immunoprecipitation-sequencing (ChIP-Seq) studies provide functional proof for the biochemically characterized HDAC interactions by showing that depletion of AML1-ETO leads to strong and global increase of histone acetylation levels at AML1-ETO target genes (Ptasinska et al., 2012; Ptasinska et al., 2014; Trombly et al., 2015). The significance of corepressor/HDAC interactions in AML1-ETO-mediated function is also supported by studies showing that inhibiting HDAC activities by HDAC inhibitors can reverse the leukemogenic phenotypes of t(8;21) cells (Klisovic et al., 2003; Barbetti et al., 2008). However, multiple domains of ETO are involved in multivalent and cooperative interactions with corepressors and HDACs (Fig. 2) (Amann et al., 2001; Hildebrand et al., 2001). In addition, corepressors may play both positive and negative roles in regulating AML1-ETO function as revealed by the increased leukemogenic activity of the AML1-ETO9a variant (see below). It thus may prove challenging to target specifically the disease-causing corepressor interactions.

The importance of repression for AML1-ETO-mediated leukemogenesis is supported by the function of AML1-ETO-downregulated genes, such as C/EBP α and Pirin, which drive myeloid differentiation; and p14/ARF, Neurofibromatosis-1, and RASSF2, which function as tumor suppressors (Table 1). Interestingly, a previous work showed that AML1-ETO can arrest cell growth and promote apoptosis (Burel et al., 2001; Hug et al., 2002). Thus, AML1-ETO may function both as an oncogene and as a tumor suppressor. It remains to be determined whether these activities reflect different doses of corepressors or coactivators recruited to AML1-ETO or its interacting proteins, and/or its context-dependent crosstalk with AML1-ETO9a and/or RUNX1, both of which can bind to AML1-ETO target genes.

A twist in the field is that while the NHR4/MYND has been mapped to be the high-affinity binding sites for NCoR/SMRT corepressors, removal of this domain converts the full-length (FL) AML1-ETO into a much more potent leukemia fusion protein (see below). Thus, unlike the FL AML1-ETO, a truncated AML1-ETO mutant lacking NHR3/4 is capable of inducing AML in the absence of compounding mutations or second hits (Yan et al., 2004). Similarly, a naturally-occurring version of this truncation, AML1-ETO9a (Fig. 1), generated by alternative splicing that removes NHR3/4, also rapidly induces AML in mice with complete penetrance (Yan et al., 2006). Clinical significance of AML1-ETO9a is provided by its association with poor prognosis of the patients (Yan et al., 2006; Jiao et al., 2009; Li et al., 2012). Subsequent studies mapped NHR4/MYND to be responsible for the lack of an inherent leukemogenic activity in the FL protein (Ahn et al., 2008). Given that other regions of AML1-ETO also mediate corepressor interactions, one may speculate that removal of the strong NCoR/SMRT-binding site may reduce the level of NCoR/SMRT/HDAC doses bound to AML1-ETO to such an “optimal” level that eliminates the growth arrest/apoptosis activity of AML1-ETO while retaining the ability to repress other cell differentiation/tumor suppressor genes (Hess and Hug, 2004). Alternatively, other NHR4 binding proteins, such as SON (Fig. 2), a cell-cycle regulator (Ahn et al., 2011), may mediate the anti-leukemogenic function of NHR4.

Role of NHR2-mediated oligomerization

Consistent with the early mapping study showing that NHR2 can function as a potent repression domain (Lutterbach et al., 1998a), NHR2-mediated oligomerization has been shown to be important for high-affinity binding of AML1-ETO/ETO to NCoR/SMRT corepressors which is reminiscent of a similar role of nuclear receptor dimerization in recruiting NCoR/SMRT corepressors (Zamir et al., 1997; Zhang et al., 2001). Independently, NHR2 also binds to Sin3A corepressor (Hildebrand et al., 2001). NHR2-mediated oligomerization has also been shown to direct AML1-ETO to duplicated AML1 sites (Okumura et al., 2008), suggesting its impact on selective binding for specific AML1 target genes. Consistent biologic studies show that NHR2 is important for AML1-ETO's leukemogenic activities. Mutating NHR2 residues to disrupt oligomerization severely impairs the abilities of AML1-ETO to inhibit granulocyte differentiation and to stimulate clonogenicity of leukemia cells (Liu et al., 2006). Serial replating assays by Kwok et al. also showed that NHR2-mediated oligomerization is required for AML1-ETO to transform mouse HSCs *in vitro*. Intriguingly, replacing NHR2 with a heterologous oligomerization domain of FKBP restores homo-oligomerization and rescues the transforming activity of AML1-ETO (Kwok et al., 2009). Finally, animal studies showed that NHR2 is required for AML1-ETO α -mediated leukemogenesis (Yan et al., 2009). Studies of PML-RAR α support the notion that oligomerization of leukemia fusion proteins may be a common mechanism of leukemogenesis (Minucci et al., 2000). These results establish NHR2 as an important therapeutic target.

AML1-ETO functions in activation

While AML1-ETO and ETO share the ability to repress transcription, AML1-ETO also gains a unique ability to activate transcription of target genes (Table 1). Unlike certain other transcription factors such as nuclear hormone receptors, AML1-ETO specifically represses and activates distinct genes, a signature that may be useful for diagnosis and treatment of t(8;21) AML (Ross et al., 2004; Valk et al., 2004). AML1-ETO-repressed and-activated genes also show overlapping and specific functions. Whereas apoptosis genes are shared by both categories, AML1-ETO appears to specifically repress differentiation genes, while activating self-renewal genes, such as JUP/plakoglobin/ γ -Catenin, which activates Wnt/ β -catenin pathway (Müller-Tidow et al., 2004; Zheng et al., 2004; Tonks et al., 2007), and Jagged1, an activator of Notch signaling (Alcalay et al., 2003). These results support multifaceted involvement of AML1-ETO in diverse pathways, including inhibition of cell differentiation, (positive and negative) regulation of apoptosis, and stimulation of self-renewal of HSCs. The latter, initially reported by several groups (Hug et al., 2002; Mulloy et al., 2002; Alcalay et al., 2003), is considered a major leukemogenic activity of AML1-ETO, which increases the pool of HSCs thereby predisposing these cells to further leukemogenic hits toward productive leukemogenesis. It should be noted that AML1-ETO target genes have been recently expanded to microRNA-coding genes, which also play important roles in AML1-ETO-mediated leukemogenesis (Fazi et al., 2007; Li et al., 2008; Chen et al., 2010; Li et al., 2013; Li et al., 2015b).

The mechanism of activation by AML1-ETO was largely elusive until several recent reports of AML1-ETO interactions with coactivators. AML1-ETO and AML1 synergistically

activate the M-CSF receptor promoter (Rhoades et al., 1996). Deletion of NHR1 renders AML1-ETO much less capable of activating the M-CSFR promoter. The p300 histone acetyltransferase (HAT) directly binds to AML1-ETO via NHR1 (Fig. 2) and mediates activation of diverse AML1-ETO target genes, including p21/WAF1, Id1, and Egr1 (Wang et al., 2011a). Mechanistically, Lys24 and Lys43 in the context of AML1-ETO and AML1-ETO9a were acetylated by p300, a PTM required for AML1-ETO9a-mediated leukemogenesis in mice. While Lys43 acetylation may facilitate subsequent transcriptional activation by recruiting the TFIID general transcription factor, it is also possible that acetylation may increase the DNA binding affinity of AML1-ETO, given the reported similar effect on RUNX1 (Yamaguchi et al., 2004), along with the effect of lysine acetylation on DNA binding by p53 (Gu and Roeder, 1997; Tang et al., 2008). In another work, PRMT1, a protein/histone arginine methyltransferase, was shown to bind to and promote transcriptional activation by AML1-ETO (Fig. 2). Underscoring the biologic importance of these interactions, both p300 and PRMT1 have been shown to be important for AML1-ETO/AML1-ETO9a-mediated oncogenic activities in vitro and in vivo (Wang et al., 2011a; Shia et al., 2012). Adding to the list of AML1-ETO co-activators, JMJD1C, a histone H3K9 demethylase, was shown to bind to (Fig. 2) and mediate AML1-ETO-dependent activation of target genes (Chen et al., 2015). JMJD1C may play a broader role in leukemogenesis given its requirement for survival of multiple human AML cell lines (Chen et al., 2015).

An unsolved mystery is how AML1-ETO distinguishes its targets to mediate activation or repression. A recent work provided some insight into this important question. It was shown that RUNX1 and AML1-ETO bind to each other and occupy adjacent but distinct motifs across the genome. The relative binding signals of RUNX1 and AML1-ETO appear to determine whether the genes are activated or repressed by AML1-ETO. Activated genes show more RUNX1 binding, and the AML1-ETO/RUNX1 complex was found to recruit AP1 to mediate transcription activation (Li et al., 2015a).

Genetic events that cooperate with AML1-ETO/AML1-ETO9a in t(8;21) leukemogenesis

Early studies using mouse models showed that AML1-ETO alone cannot induce leukemias, implying that additional mutations or secondary hits are required (Rhoades et al., 2000; Yuan et al., 2001; de Guzman et al., 2002; Higuchi et al., 2002; Mulloy et al., 2003; Fenske et al., 2004). Mutations or secondary hits that affect ASXL1, ASXL2, FLT3, KIT, NPM1, MLL, IDH1, IDH2, KRAS, NRAS, CBL, CEBPA, WT1, DNMT3A, TET2 and JAK2 have been detected in t(8;21) patients, with KIT and NRAS being the most commonly affected genes (Goemans et al., 2005; Shen et al., 2011; Krauth et al., 2014; Micol et al., 2014). Mouse models have shown that many of these secondary events can indeed cooperate with AML1-ETO and AML1-ETO9a oncogene to promote leukemogenesis.

A large cluster of mutations and secondary events directly or indirectly affect components of signal transduction pathways. Examples include activating mutations in receptor tyrosine kinases such as FLT3 (Fms-like Tyrosine Kinase 3) (Schessl et al., 2005), c-KIT (Wang et

al., 2011b; Li et al., 2015b) and TEL/PDGFR (Grisolano et al., 2003). Additionally, a NRAS G12D mutation has been reported to facilitate a stepwise process that accelerates leukemia onset (Zuber et al., 2009; Chou et al., 2011). Two studies reported the involvement of AKT pathways. Id1 has been reported to directly bind AKT and modulates its signaling activity (Wang et al., 2015). Deletion of Id1 gene postponed leukemogenesis in AML1-ETO9a-transduced mice. PTPN11 is a phosphatase acting downstream of tyrosine kinases and its D61Y mutation cooperates with AML1-ETO to induce leukemia (Hatlen et al., 2016). These changes lead to constitutive signaling through the RAF/MEK/ERK and PI3K/AKT pathways (Goemans et al., 2005; Scholl et al., 2008; Chou et al., 2011; Li et al., 2013; Yohe, 2015).

Another cluster of the mutations and secondary events affect regulators of DNA methylation. AML1-ETO is able to induce leukemia in a TET2 deficient background (Rasmussen et al., 2015; Hatlen et al., 2016). Mutations in IDH1/2 and loss-of-function mutations in WT1 also attenuate TET2 function and reduce DNA hydroxymethylation in vivo (Figueroa et al., 2010; Rampal et al., 2014). HIF1 α , a hypoxia-induced transcription factor, has been shown to cooperate with AML1-ETO to promote leukemogenesis by inducing the expression of DNMT3a, a DNA methyltransferase enzyme (Gao et al., 2015; Yohe, 2015).

A few other mutations and secondary events affect tumor suppressor, cell cycle regulator and transcription factor proteins. AML1-ETO rapidly induced leukemia when WT1 (Wilms tumor protein) was overexpressed (Nishida et al., 2006). Loss of p21/CDKN1A/CIP1/WAF1 also facilitated AML1-ETO-induced leukemogenesis (Peterson et al., 2007). In addition to HIF1 α , a recent study showed that the hematopoietic transcription factor ZBTB7A was frequently mutated in t(8;21) patients, which abolished its DNA binding activity (Hartmann et al., 2016). E-proteins also fall into this category. While the role of E-proteins in AML1-ETO-mediated leukemogenesis will be discussed in more detail in the next section, depletion of E-proteins has been shown to delay the development of t(8;21) AML in mouse models, indicating that E-proteins function as AML1-ETO cooperative factors (Sun et al., 2013).

ETO/E-protein axis in leukemogenesis and hematopoiesis

Discovery and biochemical characterization of the ETO/E-protein axis

Biochemical purification coupled with mass spectrometric identification of proteins bound to ETO identified E-proteins as stoichiometric components of AML1-ETO-containing protein complexes (Zhang et al., 2004). E-proteins, which include HEB, E2A and E2-2, comprise a family of ubiquitously-expressed basic helix–loop–helix (bHLH) transcription factors that recognize the E-box element (CANNTG) (Massari and Murre, 2000). While all three E-protein members have the ability to bind to AML1-ETO (Zhang et al., 2004; Guo et al., 2009; Gow et al., 2014), AML1-ETO associates predominately with HEB and E2A, presumably reflecting their high-level expression in hematopoietic cells. In fact, Both HEB and E2A play important roles in regulating multiple hematopoietic pathways, including lymphopoiesis (Quong et al., 2002; Kee, 2009; de Pooter and Kee, 2010), erythropoiesis (Anantharaman et al., 2011), and development of megakaryocytes (Hamlett et al., 2008) and dendritic cells (Cisse et al., 2008). E-proteins, in particular E2A, also show cell-autonomous

functions by acting as tumor suppressors and regulators of cell cycle (Engel and Murre, 1999; Zhao et al., 2001; Schwartz et al., 2006) and apoptosis (Park et al., 1999; Toyonaga et al., 2009).

At least three binding surfaces exist between AML1-ETO/ETO and E-proteins. These include the initially reported binding surface between NHR1 of ETO and AD1 (activation domain 1) of E-proteins (Zhang et al., 2004), and a subsequently identified surface between NHR2 of ETO and the DES (downstream ETO-interacting sequence) domain of E-proteins (Guo et al., 2009). A weak, yet specific interaction also exists between DES and NHR1 (Fig. 3) (Guo et al., 2009). These interactions cooperatively mediate the strong binding between E-proteins and AML1-ETO/ETO. Conserved motifs have been shown to mediate these interactions. Within AD1, PCET (p300/CBP and ETO target) mediates interactions with AML1-ETO/ETO corepressors and p300/CBP coactivators in a mutually exclusive fashion (Zhang et al., 2004). In addition to AD1, p300 also binds to AD2 of E-proteins in a manner cooperative with its binding to AD1 (Bayly et al., 2004). It has been shown that the multiple interactions of E-proteins with AML1-ETO/ETO are important for the displacement of p300 from E-proteins, thereby repressing transcription (Guo et al., 2009).

Role of ETO/E-protein axis in t(8;21) AML

Genome-wide ChIP-Seq studies demonstrated that AML1-ETO co-localizes with HEB at all their targets (Gardini et al., 2008; Martens et al., 2012; Sun et al., 2013; Ptasinska et al., 2014). These targets are enriched with both Runx and E-box elements, consistent with the notion that AML1-ETO and E-proteins selectively and cooperatively bind to DNA that contain both elements. In biological studies, while all findings are consistent with a critical importance of NHR2 (which may occur through its ability to mediate oligomerization and/or binding to DES), there are seemingly conflicting results regarding the role of NHR1. Several studies using serial replating or mouse models showed that disrupting only the PCET-NHR1 interaction via deletion or point mutations is not sufficient to abolish the oncogenic function of AML1-ETO or AML1-ETO9a (Kwok et al., 2009; Park et al., 2009a; Yan et al., 2009). However, these studies may not eliminate the “third” interaction between NHR1 and DES mentioned above, which also synergizes with the NHR2/DES interaction to achieve a strong E-protein/ETO interaction (Guo et al., 2009). Indeed, Nimer and colleagues showed that a larger deletion of NHR1 that removes this third interaction strongly reduces the leukemogenic function of AML1-ETO (Wang et al., 2011a). By using a 3D structure model (see below), Roeder and colleagues were able to differentiate NHR2 residues involved in DES binding versus oligomerization. They showed that disruption of NHR2 interaction with DES, but not NHR2-mediated oligomerization, severely compromises the ability of AML1-ETO9a to induce leukemia development (Sun et al., 2013). Depletion of E-proteins also delays leukemia development. These studies unequivocally support a critical contribution of E-proteins to AML1-ETO-mediated leukemogenesis.

The function of E-proteins extends beyond their interactions with AML1-ETO to recruiting additional factors/cofactors to AML1-ETO on target genes. Thus, AML1-ETO and E-proteins nucleate the formation of a multi-protein complex termed AETFC (AML1-ETO-containing transcription factor complex). This complex also contains CBF β , ETO-2,

MTGR1, the tissue-specific Class-II bHLH factor LYL1, and the LIM-domain protein LMO2 and its binding partner Ldb1 (Fig. 2) (Sun et al., 2013). Consistent with a bridging role for E-proteins in AML1-ETO interactions with other components of the complex, the E-protein bHLH domains interact with both Class-II factors and LMO2/Ldb1 on E-box motifs (El Omari et al., 2013). The biologic importance of the multi-protein complex was underscored by findings that these subunits co-occupy and co-regulate AML1-ETO target genes and knockdown of these subunits delays AML1-ETO9a-induced leukemogenesis (Sun et al., 2013). Collectively, these studies show that the ability of t (8;21) fusion proteins to interact with E-proteins is necessary for their abilities to deregulate gene transcription and promote leukemogenesis. Although these results support the notion that interactions with E-proteins serve the purpose for fusion proteins to inhibit E-protein's pro-differentiation and tumor suppression functions (Zhang et al., 2004), they do not prove that disrupting the normal transcriptional programs directed by E-proteins is sufficient to cause AML, which is also shown by the failure of E2A-deficient mice to develop AML. These mice, instead, develop ALL (Bain et al., 1997; Yan et al., 1997) and re-introducing E2A into the ALLs cause profound apoptosis (Engel and Murre, 1999).

The current literature is consistent with the model that the t (8;21) fusion proteins hijack E-proteins to re-program the transcriptional landscape of t(8;21) cells which results in leukemogenesis. Accordingly, in t(8;21) cells, E-proteins may have lost their "normal" tumor suppressor function and, instead, become cooperative factors of the fusion proteins. In this regard, a previous work from Kamp and colleagues showed that AML1-ETO can block the differentiation that occurred upon removal of conditionally expressed E2A-Pbx1 fusion protein in a myeloid cell line (Sykes and Kamps, 2001). While this study shows converge between different leukemogenic pathways, it also lends support to the idea that AML1-ETO expression can dominantly suppress the tumor suppressor functions of E2A that may possibly arise upon the removal of E2A-Pbx1. It is reasonable to believe that t(8;21) leukemic cells are addicted to the interactions between fusion proteins and E-proteins in order to maintain their malignant phenotypes. Therefore, targeting these interactions to segregate fusion proteins from endogenous E-proteins should prove to be a promising strategy for the development of targeted therapies for t(8;21) AML. Given that wild-type E-proteins may have functioned as cooperative factors of AML1-ETO in t(8;21) cells, introducing E-proteins into these cells may not achieve the desired tumor suppression effect. Thus, successful implementation of the targeting strategy may require introducing E-protein fragments that contain only the ETO-interacting domain but lack the DNA binding domain. Such fragments from HEB may prove to be useful given its demonstrated stronger interaction with ETO compared to that of E2A. Given the recent advance in the drug design and delivery (Azzarito et al., 2013; Higuero et al., 2013; Arkin et al., 2014; Laraia et al., 2015), developing small chemicals and peptidomimetics inhibitors that mimic these E-protein fragments to specifically block E-protein/AML1-ETO interactions are likely to be useful drugs for the treatment of t (8;21) AML.

Role of ETO/E-protein axis in other leukemogenic and normal hematopoiesis pathways

Previous studies have established functional importance of the E2A activation domain-mediated transcriptional activation for E2A-Pbx1's leukemogenic function (Kamps and

Baltimore, 1993; Lu et al., 1994; Geng et al., 2012). Both E2A and E2A-Pbx1 recruit p300/CBP via direct and cooperative binding via AD1 and AD2 (Bayly et al., 2004; Denis et al., 2014). AD1 in this context appears to be especially important given that a single mutation of a conserved Leu within PCET, which disrupts p300 interaction, also disrupts the leukemogenic function of E2A-Pbx1 (Bayly et al., 2006).

We reported a striking difference between E2A-AD1 and HEB-AD1 in the ability to bind ETO family corepressors including ETO-2. Remarkably, replacing E2A-AD1 with HEB-AD1 in the context of E2A-Pbx1 completely abolishes its abilities to mediate transcriptional activation of key target genes and to transform cells (Gow et al., 2014). This has been attributed to three amino acid differences at the C terminus of PCET between E2A-AD1 and HEB-AD1 (Fig. 4A), which specifically weaken E2A-AD1-corepressor interaction but not E2A-AD1-coactivator interaction. Thus, the transcriptional and oncogenic functions of E2A-Pbx1 not only depend on its ability to recruit p300, but also depend on its ability to bypass interactions with ETO corepressors such as ETO-2, which is expressed at high levels in B cells. The changes of E2A-AD1 sequence, however, do not completely abolish the sensitivity of E2A to repression by ETO corepressors. In t(8;21) cells, a high-level expression of AML1-ETO overcomes the reduced binding affinity with E2A, allowing AML1-ETO to bind and consequently suppress E2A target genes involved in tumor suppressor function (Engel and Murre, 1999; Gow et al., 2014). In t(1;19) leukemia cells, E2A-Pbx1 exploits the unique feature of the E2A-AD1 sequence to bypass ETO-2 interaction and repression, thereby ensuring activation of the oncogenic E2A-Pbx1 target genes to promote leukemogenesis (Fig. 4B,C) (Lu et al., 1995; Gow et al., 2014). These studies reveal context-dependent roles of ETO/E-protein interactions in distinct leukemogenic pathways, and highlight the importance of understanding the mechanisms of individual leukemia fusion proteins for effective targeting in therapeutic interventions.

ETO-2/E-protein interaction also facilitates the formation of a multi-protein corepressor complex containing ETO-2, MTGR1, E2A/HEB, TAL1/SCL, LMO2, Ldb1, and GATA1 (Schuh et al., 2005; Goardon et al., 2006). In this complex, ETO-2 serves a gatekeeper role by repressing E-protein/TAL1/GATA1 target genes, thereby preventing the premature differentiation into erythrocytes and megakaryocytes (Goardon et al., 2006; Hamlett et al., 2008). ETO-2 also plays an important role in regulating HSCs. An early study showed that ETO-2 is indispensable for definitive hematopoiesis in zebrafish (Meier et al., 2006). Subsequent studies showed that ETO-2 is required for cell fate decision and proliferation of early HSCs in mice (Chyla et al., 2008). ETO-2^{-/-} bone marrow cells fail to transplant recipient mice due to a loss of self-renewal activity (Fischer et al., 2012). Consistently, ETO-2-deficient long-term HSCs showed cell-cycle blockage at the S phase (Fischer et al., 2012). A recent work showed that loss of ETO-2 compromises T cell development (Hunt et al., 2011). While this finding is consistent with ETO-2 regulation of E-protein's transcriptional activities, it seems incompatible with a corepressor function of ETO-2, given that E-proteins are positive regulators of T cell development. It is possible that the observed defects in T cell development reflect a defect of HSCs given the aforementioned role of ETO-2 in HSC regulation, along with the diminished Notch activity in ETO-2-deficient cells (Chyla et al., 2008; Hunt et al., 2011).

Structural insights into AML1-ETO functions

The structure of the RHD domain has been studied in the context of RUNX1, whereas ETO domain structures have only been reported recently. In this section, we provide a summary of these studies (Table 2), along with a brief discussion of their functional implications.

Runt-homology domain structures

Both free and complexed forms of RHD with and without DNA have been reported (Table 2). Overall, RHD assumes an all- β structure characteristic of the S-type immunoglobulin (Ig) fold that is also observed in DNA binding domains of p53 and NF κ B (Cho et al., 1994; Chen et al., 1998; Nagata et al., 1999). RHD binds to DNA through the bottom loops and the C-terminal tail (Bravo et al., 2001; Tahirov et al., 2001). The opposite side of the structure mediates interactions with CBF β , which consists of a β -sandwich surrounded by 4 α -helices (Fig. 5) (Huang et al., 1999; Warren et al., 2000; Bravo et al., 2001; Tahirov et al., 2001). These structural studies explain how CBF β increases the DNA binding affinity of RUNX1 and indicate that CBF β may play a similar role in facilitating DNA binding by AML1-ETO, which is required for its leukemogenic function (Matheny et al., 2007; Yan et al., 2009). There are, however, conflicting reports on the role of CBF β in AML1-ETO's leukemogenic activity (Kwok et al., 2009; Park et al., 2009b; Roudaia et al., 2009; Kwok et al., 2010). These discrepancies may result from the use of different assays and their different sensitivities to the change of binding affinity between AML1-ETO and CBF β .

NHR1/eTAFH domain structures

Three NHR1-containing structures have been solved by nuclear magnetic resonance (NMR) (Plevin et al., 2006; Wei et al., 2007; Park et al., 2009a) (Table 2). NHR1 folds into a four-helix bundle (α 1– α 4) structure. This fold is similar to the paired amphipathic helix (PAH) domain of Sin3A (Plevin et al., 2006). Although the overall folding of NHR1 is similar among the three reported structures, the C-termini of α 4 differ significantly, suggesting that it may have a flexible conformation in native proteins. The PCET binding site is located at a groove formed by α 1 and α 4 helices. Three conserved Leu residues in the LXXLL motif of PCET anchor the PCET to the α 1/ α 4 groove (Fig. 5) (Park et al., 2009a).

Given the different binding affinity between HEB-AD1 and E2A-AD1 to NHR1, we modeled both HEB-AD1/NHR1 and E2A-AD1/NHR1 complex structures, using a longer PCET polypeptide that includes the three isoform-specific amino acids (Fig. 4A). The result showed that a Ser to Pro change in E2A PCET abolishes an H-bond interaction with a conserved Arg151 that has been previously shown to contribute to binding with HEB-AD1. In addition, the two Asp residues in the PCET motif form two salt bridges with Lys98 in HEB-AD1/NHR1 structure, but only one remains in E2A-AD1/NHR1 structure. Taken together, our docking analysis uncovered that the reduced E2A-AD1/NHR1 interaction is due to structural incompatibility with the high-affinity binding conformation (Gow et al., 2014).

The LXXLL motif in PCET is a common protein–protein interaction motif (Heery et al., 1997). In addition to its role in mediating ETO/E-protein interaction, the ETO-NHR1 (also

called eTAFH) has also been shown to bind with lower affinities to NCoR, c-Myb and STAT6 via similar LXXLL motifs present in these proteins (Wei et al., 2007; Park et al., 2009a). ETO-TAFH and its homologous TAF4-TAFH (dTAFH) share similar secondary and tertiary structures. Accordingly, dTAFH uses a similar hydrophobic cleft between $\alpha 1$ and $\alpha 4$ to interact with transcription factors such as LZIP and E2F4 (Wang et al., 2007).

NHR2 domain structures

NHR2 is one of the most conserved regions in ETO family proteins. The first crystal structure of NHR2 was reported by Bushweller group (Liu et al., 2006). Four identical α -helical NHR2 polypeptides assemble into a tetrameric structure consisting of two anti-parallel-oriented dimers (Fig. 5). Site-directed mutagenesis of critical residues required for oligomerization of NHR2, but not for corepressor interactions, showed that the oligomeric potential of AML1-ETO is indispensable for its inhibition of granulocyte differentiation and enhancement of HSCs self-renewal (Liu et al., 2006).

The NHR2 of AML1-ETO also binds to E-proteins (Guo et al., 2009). Roeder and colleagues showed that NHR2/DES interaction is actually dependent on NHR2-mediated oligomerization (Sun et al., 2013). Each of the NHR2 dimers within the tetrameric structure creates a novel binding surface for the DES/N2B polypeptide (Fig. 5). As mentioned earlier, selective disruption of NHR2/N2B interaction, but not oligomerization, impaired the leukemogenic activities of both AML1-ETO and AML1-ETO9a (Sun et al., 2013).

NHR3 and NHR4 domain structures

NHR3 shares some sequence homology with A-kinase anchoring proteins (AKAP), which act as scaffold proteins to associate with cyclic AMP-dependent protein kinase (PKA) (Fukuyama et al., 2001). The structure of NHR3-PKA (RII α) complex revealed that NHR3 folds into an amphipathic α -helix which lies on a surface formed by a dimeric PKA (RII α) (Fig. 5). Functional studies, however, argue against an important role of this interaction in AML1-ETO's leukemogenic activities (Corpora et al., 2010; Kwok et al., 2010).

NHR4/MYND mediates AML1-ETO/ETO interactions with NCoR/SMRT (Gelmetti et al., 1998; Lutterbach et al., 1998b; Wang et al., 1998), and a second NCoR/SMRT binding site lies in ETO N-terminal part (Lutterbach et al., 1998b; Amann et al., 2001; Wei et al., 2007). The MYND/SMRT complex structure shows that MYND coordinates two zinc atoms in a manner similar to PHD and RING fingers (Gamsjaeger et al., 2007; Liu et al., 2007). MYND bound to the "PPPLI" motif present in the RD3 of SMRT to form a pair of short anti-parallel β -strands (Fig. 5). Disrupting MYND-SMRT interaction significantly altered AML1-ETO-dependent gene expression patterns but does not compromise its granulocyte differentiation inhibition function (Liu et al., 2007).

Conclusion and future directions

Since the discovery of the AML1-ETO fusion protein nearly 30 years ago, tremendous progress has been made to understand the mechanism and function of this fusion protein, including its regulation of target gene transcription, and its involvement in diverse pathways that impact on cell proliferation, differentiation, apoptosis and survival. Major advances have

been made in areas of biochemical, genomic and structural studies, which provide new insights into (i) the interacting proteins of the fusion protein, (ii) the genome-wide target genes, and (iii) the atomic structures of functional domains. These studies have reinforced the idea that the fusion protein functions as a “classic” transcription factor and also established “ETO/E-protein axis” as a common axis that governs the activity of multiple leukemia fusion proteins. However, despite the major progress made in the recent years, to date, we are still far from obtaining a complete understanding of the mechanisms, function and regulation of the fusion proteins and their binding partners in normal and leukemia cells. Future studies may be directed to a further understanding of (i) the determinants that govern gene-specific activation and repression of AML1-ETO target genes; (ii) the isoform-specific function of AML1-ETO and AML1-ETO9a, (iii) the crosstalk between AML1-ETO and interacting proteins, including RUNX1 and E-proteins, (iv) the mechanism that controls the splicing of the t(8;21) fusion gene, (v) the role of the ETO family proteins in regulating the leukemia fusion proteins, and (vi) “ETO/E-protein” axis in these regulations as well as its utility as a common druggable target in leukemias. While preventing the interactions with E-proteins is expected to inactivate t(8;21) fusion proteins in AML, enhancing the binding of ETO corepressors to E2A fusion proteins is expected to provide a new means to inactivate E2A fusion proteins in ALL. Though structural studies have uncovered new mechanisms associated with the individual domains and domain interactions, it will be important to elucidate the complete structure including protein–protein interactions that occur in the context of native proteins in living cells. Given that the AML1-ETO and E2A fusion proteins exert their functions as transcription factors, their protein–protein interactions should serve as important druggable targets for leukemia therapy.

Acknowledgments

This work is supported by National Institutes of Health grants R01HL093195, R21CA178513 (to J.Z.) and by the President's Research Fund from Saint Louis University (to J.Z.) We apologize for not being able to cite all related references in this review due to length limitations in the main text and references.

References

- Ahn EY, DeKolver RC, Lo MC, Nguyen TA, Matsuura S, Boyapati A, Pandit S, Fu XD, Zhang DE. SON controls cell-cycle progression by coordinated regulation of RNA splicing. *Mol Cell*. 2011; 42(2):185–198. [PubMed: 21504830]
- Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. *Proc Natl Acad Sci USA*. 2008; 105(44):17103–17108. [PubMed: 18952841]
- Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C, Sciarpi MT, Mariano AR, Minardi SP, Luzi L, Muller H, Di Fiore PP, Frosina G, Pelicci PG. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. *J Clin Invest*. 2003; 112(11):1751–1761. [PubMed: 14660751]
- Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. *Mol Cell Biol*. 2001; 21(19): 6470–6483. [PubMed: 11533236]
- Anantharaman A, Lin IJ, Barrow J, Liang SY, Masannat J, Strouboulis J, Huang S, Bungert J. Role of helix-loop-helix proteins during differentiation of erythroid cells. *Mol Cell Biol*. 2011; 31(7):1332–1343. [PubMed: 21282467]

- Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. *Chem Biol*. 2014; 21(9):1102–1114. [PubMed: 25237857]
- Aspland SE, Bendall HH, Murre C. The role of E2A-PBX1 in leukemogenesis. *Oncogene*. 2001; 20(40):5708–5717. [PubMed: 11607820]
- Azzarito V, Long K, Murphy NS, Wilson AJ. Inhibition of α -helix-mediated protein-protein interactions using designed molecules. *Nat Chem*. 2013; 5(3):161–173. [PubMed: 23422557]
- Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL, Chun J, Huey B, Pinkel D, Murre C. E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. *Mol Cell Biol*. 1997; 17(8):4782–4791. [PubMed: 9234734]
- Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. *Oncogene*. 2008; 27(12):1767–1778. [PubMed: 17891169]
- Bartfeld D, Shimon L, Couture GC, Rabinovich D, Frolov F, Levanon D, Groner Y, Shakked Z. DNA recognition by the RUNX1 transcription factor is mediated by an allosteric transition in the RUNT domain and by DNA bending. *Structure*. 2002; 10(10):1395–1407. [PubMed: 12377125]
- Bayly R, Chuen L, Currie RA, Hyndman BD, Casselman R, Blobel GA, LeBrun DP. E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells. *J Biol Chem*. 2004; 279(53):55362–55371. [PubMed: 15507449]
- Bayly R, Murase T, Hyndman BD, Savage R, Nurmohamed S, Munro K, Casselman R, Smith SP, LeBrun DP. Critical role for a single leucine residue in leukemia induction by E2A-PBX1. *Mol Cell Biol*. 2006; 26(17):6442–6452. [PubMed: 16914730]
- Berardi MJ, Sun C, Zehr M, Abildgaard F, Peng J, Speck NA, Bushweller JH. The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. *Structure*. 1999; 7(10):1247–1256. [PubMed: 10545320]
- Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (Runx1)—CBF beta complex functions as a DNA-induced molecular clamp. *Nat Struct Biol*. 2001; 8(4):371–378. [PubMed: 11276260]
- Breig O, Bras S, Martinez Soria N, Osman D, Heidenreich O, Haenlin M, Waltzer L. Pontin is a critical regulator for AML1-ETO-induced leukemia. *Leukemia*. 2014; 28(6):1271–1279. [PubMed: 24342949]
- Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. *Mol Cell Biol*. 2001; 21(16):5577–5590. [PubMed: 11463839]
- Calabi F, Cilli V. CBFA2T1, a gene rearranged in human leukemia, is a member of a multigene family. *Genomics*. 1998; 52(3):332–341. [PubMed: 9790752]
- Calabi F, Pannell R, Pavloska G. Gene targeting reveals a crucial role for MTG8 in the gut. *Mol Cell Biol*. 2001; 21(16):5658–5666. [PubMed: 11463846]
- Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. *Oncogene*. 1993; 8(4):983–988. [PubMed: 8455949]
- Chen FE, Huang DB, Chen YQ, Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA. *Nature*. 1998; 391(6665):410–413. [PubMed: 9450761]
- Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. *Nat Rev Cancer*. 2010; 10(1):23–36. [PubMed: 20029422]
- Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA, Roeder RG. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. *Genes Dev*. 2015; 29(20):2123–2139. [PubMed: 26494788]
- Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ, Licht JD, Melnick A. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. *Blood*. 2004; 103(4):1454–1463. [PubMed: 14551142]
- Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science*. 1994; 265(5170):346–355. [PubMed: 8023157]
- Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and

self-renewal in human preleukemia induced by AML1-ETO. *Blood*. 2012; 120(4):709–719. [PubMed: 22337712]

Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras (G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. *Blood*. 2011; 117(7):2237–2240. [PubMed: 21200020]

Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, Engel M, Hiebert SW. Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. *Mol Cell Biol*. 2008; 28(20):6234–6247. [PubMed: 18710942]

Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, Locksley R, Holmberg D, Zweier C, den Hollander NS, Kant SG, Holter W, Rauch A, Zhuang Y, Reizis B. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. *Cell*. 2008; 135(1):37–48. [PubMed: 18854153]

Corpora T, Roudaia L, Oo ZM, Chen W, Manuylova E, Cai X, Chen MJ, Cierpicki T, Speck NA, Bushweller JH. Structure of the AML1-ETO NHR3-PKA(RII α) complex and its contribution to AML1-ETO activity. *J Mol Biol*. 2010; 402(3):560–577. [PubMed: 20708017]

D'Alonzo RC, Selvamurugan N, Karsenty G, Partridge NC. Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation. *J Biol Chem*. 2002; 277(1):816–822. [PubMed: 11641401]

Davis JN, Williams BJ, Herron JT, Galiano FJ, Meyers S. ETO-2, a new member of the ETO-family of nuclear proteins. *Oncogene*. 1999; 18(6):1375–1383. [PubMed: 10022820]

de Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function. *Oncogene*. 2004; 23(24):4238–4248. [PubMed: 15156179]

de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. *Mol Cell Biol*. 2002; 22(15):5506–5517. [PubMed: 12101243]

de Pooter RF, Kee BL. E proteins and the regulation of early lymphocyte development. *Immunol Rev*. 2010; 238(1):93–109. [PubMed: 20969587]

Denis CM, Langelaan DN, Kirilina AC, Chitayat S, Munro K, Spencer HL, LeBrun DP, Smith SP. Functional redundancy between the transcriptional activation domains of E2A is mediated by binding to the KIX domain of CBP/p300. *Nucleic Acids Res*. 2014; 42(11):7370–7382. [PubMed: 24682819]

Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. *Br J Haematol*. 1999; 106(2):296–308. [PubMed: 10460585]

El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Hall-Ponsel E, Platonova O, Vyas P, Patient R, Porcher C, Mancini EJ. Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets. *Cell Reports*. 2013; 4(1):135–147. [PubMed: 23831025]

Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. *Blood*. 2003; 101(11):4333–4341. [PubMed: 12576332]

Engel I, Murre C. Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas. *Proc Natl Acad Sci USA*. 1999; 96(3):996–1001. [PubMed: 9927682]

Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to *Drosophila* segmentation gene, runt. *Blood*. 1992; 80(7):1825–1831. [PubMed: 1391946]

Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA. ETO and AML1 phosphoproteins are expressed in CD34 + hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. *Blood*. 1996; 88(5):1813–1823. [PubMed: 8781439]

Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. *Cancer Res*. 1994; 54(7):1782–1786. [PubMed: 8137293]

- Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F, Grignani F, Nervi C. Epigenetic silencing of the myelopoiesis regulator micro-RNA-223 by the AML1/ETO oncoprotein. *Cancer Cell*. 2007; 12(5):457–466. [PubMed: 17996649]
- Feinstein PG, Kornfeld K, Hogness DS, Mann RS. Identification of homeotic target genes in *Drosophila melanogaster* including *nervy*, a proto-oncogene homologue. *Genetics*. 1995; 140(2): 573–586. [PubMed: 7498738]
- Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. *Proc Natl Acad Sci USA*. 2004; 101(42):15184–15189. [PubMed: 15477599]
- Figuerola ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010; 18(6):553–567. [PubMed: 21130701]
- Fischer MA, Moreno-Miralles I, Hunt A, Chyla BJ, Hiebert SW. Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence. *EMBO J*. 2012; 31(6):1494–1505. [PubMed: 22266796]
- Fracchiolla NS, Colombo G, Finelli P, Maiolo AT, Neri A. EHT, a new member of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute myeloid leukemias. *Blood*. 1998; 92(9): 3481–3484. [PubMed: 9787195]
- Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. *Oncogene*. 1995; 11(12):2667–2674. [PubMed: 8545124]
- Fukuyama T, Sueoka E, Sugio Y, Otsuka T, Niho Y, Akagi K, Kozu T. MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes. *Oncogene*. 2001; 20(43):6225–6232. [PubMed: 11593431]
- Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8 (ETO) family. *Blood*. 1998; 91(11):4028–4037. [PubMed: 9596646]
- Gamsjaeger R, Liew CK, Loughlin FE, Crossley M, Mackay JP. Sticky fingers: zinc-fingers as protein-recognition motifs. *Trends Biochem Sci*. 2007; 32(2):63–70. [PubMed: 17210253]
- Gao XN, Yan F, Lin J, Gao L, Lu XL, Wei SC, Shen N, Pang JX, Ning QY, Komeno Y, Deng AL, Xu YH, Shi JL, Li YH, Zhang DE, Nervi C, Liu SJ, Yu L. AML1/ETO cooperates with HIF1 α to promote leukemogenesis through DNMT3a transactivation. *Leukemia*. 2015; 29(8):1730–1740. [PubMed: 25727291]
- Gardini A, Cesaroni M, Luzi L, Okumura AJ, Biggs JR, Minardi SP, Venturini E, Zhang DE, Pelicci PG, Alcalay M. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. *PLoS Genet*. 2008; 4(11):e1000275. [PubMed: 19043539]
- Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. *Mol Cell Biol*. 1998; 18(12):7185–7191. [PubMed: 9819405]
- Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discov*. 2012; 2(11):1004–1023. [PubMed: 23107779]
- Gordon N, Lambert JA, Rodriguez P, Nissaire P, Herblot S, Thibault P, Dumenil D, Strouboulis J, Romeo PH, Hoang T. ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. *EMBO J*. 2006; 25(2):357–366. [PubMed: 16407974]
- Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hählen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia*. 2005; 19(9):1536–1542. [PubMed: 16015387]

- Gow CH, Guo C, Wang D, Hu Q, Zhang J. Differential involvement of E2A-corepressor interactions in distinct leukemogenic pathways. *Nucleic Acids Res.* 2014; 42(1):137–152. [PubMed: 24064250]
- Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFBetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. *Proc Natl Acad Sci USA.* 2003; 100(16):9506–9511. [PubMed: 12881486]
- Gross CT, McGinnis W. DEAF-1, a novel protein that binds an essential region in a Deformed response element. *EMBO J.* 1996; 15(8):1961–1970. [PubMed: 8617243]
- Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. *Cell.* 1997; 90(4):595–606. [PubMed: 9288740]
- Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhata R. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. *Genes Dev.* 2000; 14(9):1048–1057. [PubMed: 10809664]
- Guo C, Hu Q, Yan C, Zhang J. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery. *Mol Cell Biol.* 2009; 29(10):2644–2657. [PubMed: 19289505]
- Hamlett I, Draper J, Strouboulis J, Iborra F, Porcher C, Vyas P. Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. *Blood.* 2008; 112(7):2738–2749. [PubMed: 18625887]
- Hartmann L, Dutta S, Opatz S, Vosberg S, Reiter K, Leubolt G, Metzeler KH, Herold T, Bamopoulos SA, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Hopfner KP, Graf A, Krebs S, Blum H, Middeke JM, Stölzel F, Thiede C, Wolf S, Bohlander SK, Preiss C, Chen-Wichmann L, Wichmann C, Sauerland MC, Büchner T, Berdel WE, Wörmann BJ, Braess J, Hiddemann W, Spiekermann K, Greif PA. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. *Nat Commun.* 2016; 7:11733. [PubMed: 27252013]
- Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. *Cell.* 1997; 89(3):341–347. [PubMed: 9150133]
- Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, Gonen M, Levine RL, Nimer SD. Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. *J Exp Med.* 2016; 213(1):25–34. [PubMed: 26666262]
- Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature.* 1997; 387(6634):733–736. [PubMed: 9192902]
- Heinzel T, Lavinsky RM, Mullen TM, Söderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. *Nature.* 1997; 387(6628):43–48. [PubMed: 9139820]
- Hess JL, Hug BA. Fusion-protein truncation provides new insights into leukemogenesis. *Proc Natl Acad Sci USA.* 2004; 101(49):16985–16986. [PubMed: 15572447]
- Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. *Cancer Cell.* 2002; 1(1):63–74. [PubMed: 12086889]
- Higueruelo AP, Jubb H, Blundell TL. Protein-protein interactions as druggable targets: recent technological advances. *Curr Opin Pharmacol.* 2013; 13(5):791–796. [PubMed: 23735579]
- Hildebrand D, Tiefenbach J, Heinzel T, Grez M, Maurer AB. Multiple regions of ETO cooperate in transcriptional repression. *J Biol Chem.* 2001; 276(13):9889–9895. [PubMed: 11150306]
- Huang X, Peng JW, Speck NA, Bushweller JH. Solution structure of core binding factor beta and map of the CBF alpha binding site. *Nat Struct Biol.* 1999; 6(7):624–627. [PubMed: 10404216]
- Hug BA, Lee SY, Kinsler EL, Zhang J, Lazar MA. Cooperative function of Aml1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells. *Cancer Res.* 2002; 62(10):2906–2912. [PubMed: 12019171]
- Hunt A, Fischer M, Engel ME, Hiebert SW. Mtg16/Eto2 contributes to murine T-cell development. *Mol Cell Biol.* 2011; 31(13):2544–2551. [PubMed: 21536648]

- Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD, Look AT. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. *Science*. 1992; 257(5069):531–534. [PubMed: 1386162]
- Ito Y. Oncogenic potential of the RUNX gene family: ‘overview’. *Oncogene*. 2004; 23(24):4198–4208. [PubMed: 15156173]
- Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SD. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. *J Biol Chem*. 2000; 275(51):40282–40287. [PubMed: 11032826]
- Jankovic V, Ciarrocchi A, Boccuni P, DeBlasio T, Benezra R, Nimer SD. Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. *Proc Natl Acad Sci USA*. 2007; 104(4):1260–1265. [PubMed: 17227850]
- Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B, Shi JY, Wang YY, Wang JH, Chen Y, Li JM, Gu LJ, Tang JY, Shen ZX, Gu BW, Zhao WL, Chen Z, Chen SJ. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. *Leukemia*. 2009; 23(9):1598–1604. [PubMed: 19458628]
- Jin W, Wu K, Li YZ, Yang WT, Zou B, Zhang F, Zhang J, Wang KK. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. *Oncogene*. 2013; 32(15):1978–1987. [PubMed: 22641217]
- Kamps MP, Baltimore D. E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. *Mol Cell Biol*. 1993; 13(1):351–357. [PubMed: 8093327]
- Kamps MP, Murre C, Sun XH, Baltimore D. A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. *Cell*. 1990; 60(4):547–555. [PubMed: 1967983]
- Kee BL. E and ID proteins branch out. *Nat Rev Immunol*. 2009; 9(3):175–184. [PubMed: 19240756]
- Kim WY, Sieweke M, Ogawa E, Wee HJ, Englmeier U, Graf T, Ito Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. *EMBO J*. 1999; 18(6):1609–1620. [PubMed: 10075931]
- Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K, Nomura N, Hayashi Y, Ohki M. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. *Mol Cell Biol*. 1998; 18(2):846–858. [PubMed: 9447981]
- Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. *Proc Natl Acad Sci USA*. 1996; 93(24):14059–14064. [PubMed: 8943060]
- Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. *Leukemia*. 2003; 17(2):350–358. [PubMed: 12592335]
- Komori A, Sueoka E, Fujiki H, Ishii M, Kozu T. Association of MTG8 (ETO/CDR), a leukemia-related protein, with serine/threonine protein kinases and heat shock protein HSP90 in human hematopoietic cell lines. *Jpn J Cancer Res*. 1999; 90(1):60–68. [PubMed: 10076566]
- Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. *Leukemia*. 2014; 28(7):1449–1458. [PubMed: 24402164]
- Kwok C, Zeisig BB, Dong S, So CW. The role of CBFbeta in AML1-ETO’s activity. *Blood*. 2010; 115(15):3176–3177. [PubMed: 20395424]
- Kwok C, Zeisig BB, Qiu J, Dong S, So CW. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. *Proc Natl Acad Sci USA*. 2009; 106(8):2853–2858. [PubMed: 19202074]
- Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. *Cell*. 1997; 89(3):349–356. [PubMed: 9150134]

- Laraia L, McKenzie G, Spring DR, Venkitaraman AR, Huggins DJ. Overcoming chemical, biological, and computational challenges in the development of inhibitors targeting protein-protein interactions. *Chem Biol.* 2015; 22(6):689–703. [PubMed: 26091166]
- Lenny N, Meyers S, Hiebert SW. Functional domains of the t (8;21) fusion protein, AML-1/ETO. *Oncogene.* 1995; 11(9):1761–1769. [PubMed: 7478604]
- Li FQ, Person RE, Takemaru K, Williams K, Meade-White K, Ozsahin AH, Güngör T, Moon RT, Horwitz M. Lymphoid enhancer factor-1 links two hereditary leukemia syndromes through core-binding factor alpha regulation of ELA2. *J Biol Chem.* 2004; 279(4):2873–2884. [PubMed: 14594802]
- Li J, Wang J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. *EMBO J.* 2000; 19(16):4342–4350. [PubMed: 10944117]
- Li LM, Chen ZX, Cen JN, Shen HJ, Yao L, Wang YY, Qi XF. Monitoring the expression ratio of AML1-ETO9a isoform in t(8;21) acute myeloid leukemia and its significance. *Zhonghua Xue Ye Xue Za Zhi.* 2012; 33(1):1–5. [PubMed: 22575183]
- Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. *Cell.* 2002; 109(1):113–124. [PubMed: 11955451]
- Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C, Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, Bloomfield CD, Marcucci G, Yu L. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. *Blood.* 2013; 121(3):499–509. [PubMed: 23223432]
- Li Y, Wang H, Wang X, Jin W, Tan Y, Fang H, Chen S, Chen Z, Wang K. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. *Blood.* 2015a; 127(2):233–242. [PubMed: 26546158]
- Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Aronovitz S, He M, Gurbuxani S, Zuo Z, Elkahoul AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. Overexpression and knockout of miR-126 both promote leukemogenesis. *Blood.* 2015b; 126(17):2005–2015. [PubMed: 26361793]
- Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. *Proc Natl Acad Sci USA.* 2008; 105(40):15535–15540. [PubMed: 18832181]
- Liebermann TA, Pan Z, Akbarali Y, Hetherington CJ, Boltax J, Yergeau DA, Zhang DE. AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. *J Biol Chem.* 1999; 274(35):24671–24676. [PubMed: 10455134]
- Licciulli S, Cambiaghi V, Scafetta G, Gruszka AM, Alcalay M. Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation. *Leukemia.* 2010; 24(2):429–437. [PubMed: 20010624]
- Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. *Nat Med.* 2002; 8(7):743–750. [PubMed: 12091906]
- Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, Yu J, Becknell B, Li Y, Liu C, Vukosavljevic T, Whitman SP, Chang KS, Byrd JC, Perrotti D, Plass C, Marcucci G. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. *Cancer Res.* 2005; 65(4):1277–1284. [PubMed: 15735013]
- Liu Y, Chen W, Gaudet J, Cheney MD, Roudaia L, Cierpicki T, Klet RC, Hartman K, Laue TM, Speck NA, Bushweller JH. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. *Cancer Cell.* 2007; 11(6):483–497. [PubMed: 17560331]

- Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D, Lary J, Cole J, Dauter Z, Minor W, Speck NA, Bushweller JH. The tetramer structure of the Nrvy homology two domain, NHR2, is critical for AML1/ETO's activity. *Cancer Cell*. 2006; 9(4):249–260. [PubMed: 16616331]
- Lo MC, Peterson LF, Yan M, Cong X, Jin F, Shia WJ, Matsuura S, Ahn EY, Komeno Y, Ly M, Ommen HB, Chen IM, Hokland P, Willman CL, Ren B, Zhang DE. Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. *Blood*. 2012; 120(7):1473–1484. [PubMed: 22740448]
- Lotem J, Levanon D, Negreanu V, Bauer O, Hantisteanu S, Dicken J, Groner Y. Runx3 at the interface of immunity, inflammation and cancer. *Biochim Biophys Acta*. 2015; 1855(2):131–143. [PubMed: 25641675]
- Lu Q, Knoepfler PS, Scheele J, Wright DD, Kamps MP. Both Pbx1 and E2A-Pbx1 bind the DNA motif ATCAATCAA cooperatively with the products of multiple murine Hox genes, some of which are themselves oncogenes. *Mol Cell Biol*. 1995; 15(7):3786–3795. [PubMed: 7791786]
- Lu Q, Wright DD, Kamps MP. Fusion with E2A converts the Pbx1 homeodomain protein into a constitutive transcriptional activator in human leukemias carrying the t(1;19) translocation. *Mol Cell Biol*. 1994; 14(6):3938–3948. [PubMed: 7910944]
- Lutterbach B, Sun D, Schuetz J, Hiebert SW. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. *Mol Cell Biol*. 1998a; 18(6):3604–3611. [PubMed: 9584201]
- Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. *Mol Cell Biol*. 1998b; 18(12):7176–7184. [PubMed: 9819404]
- Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. *Mol Cell Biol*. 1999; 19(5):3635–3644. [PubMed: 10207087]
- Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. *Blood*. 2012; 120(19):4038–4048. [PubMed: 22983443]
- Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. *Mol Cell Biol*. 2000; 20(2):429–440. [PubMed: 10611221]
- Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M, Newman M, Roudaia L, Speck CL, Gu TL, Griffey SM, Bushweller JH, Speck NA. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. *EMBO J*. 2007; 26(4):1163–1175. [PubMed: 17290219]
- McGhee L, Bryan J, Elliott L, Grimes HL, Kazanjian A, Davis JN, Meyers S. Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism. *J Cell Biochem*. 2003; 89(5):1005–1018. [PubMed: 12874834]
- Meier N, Krpic S, Rodriguez P, Strouboulis J, Monti M, Krijgsveld J, Gering M, Patient R, Hostert A, Grosveld F. Novel binding partners of Ldb1 are required for haematopoietic development. *Development*. 2006; 133(24):4913–4923. [PubMed: 17108004]
- Mellentin JD, Murre C, Donlon TA, McCaw PS, Smith SD, Carroll AJ, McDonald ME, Baltimore D, Cleary ML. The gene for enhancer binding proteins E12/E47 lies at the t(1;19) breakpoint in acute leukemias. *Science*. 1989; 246(4928):379–382. [PubMed: 2799390]
- Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW, Licht JD. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. *Mol Cell Biol*. 2000; 20(6):2075–2086. [PubMed: 10688654]
- Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. *Mol Cell Biol*. 1993; 13(10):6336–6345. [PubMed: 8413232]

- Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. *Mol Cell Biol.* 1995; 15(4):1974–1982. [PubMed: 7891692]
- Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. *Blood.* 2014; 124(9):1445–1449. [PubMed: 24973361]
- Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. *Mol Cell.* 2000; 5(5):811–820. [PubMed: 10882117]
- Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. *EMBO J.* 1993; 12(7):2715–2721. [PubMed: 8334990]
- Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E, Ohki M. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. *Nucleic Acids Res.* 1995; 23(14):2762–2769. [PubMed: 7651838]
- Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. *Proc Natl Acad Sci USA.* 1991; 88(23):10431–10434. [PubMed: 1720541]
- Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Köhler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. *Mol Cell Biol.* 2004; 24(7):2890–2904. [PubMed: 15024077]
- Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34 + hematopoietic cells using a single genetic element. *Blood.* 2003; 102(13):4369–4376. [PubMed: 12946995]
- Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. *Blood.* 2002; 99(1): 15–23. [PubMed: 11756147]
- Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O, Zhao H, Valk PJ, Lowenberg B, Nimer SD. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34 + cells, allowing nerve growth factor-induced expansion. *Proc Natl Acad Sci USA.* 2005; 102(11):4016–4021. [PubMed: 15731354]
- Nagata T, Gupta V, Sorce D, Kim WY, Sali A, Chait BT, Shigesada K, Ito Y, Werner MH. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. *Nat Struct Biol.* 1999; 6(7):615–619. [PubMed: 10404214]
- Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. *Cell.* 1997; 89(3):373–380. [PubMed: 9150137]
- Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. *Blood.* 2006; 107(8):3303–3312. [PubMed: 16380455]
- Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, Cleary ML. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. *Cell.* 1990; 60(4):535–545. [PubMed: 1967982]
- Ogawa E, Inuzuka M, Maruyama M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. *Virology.* 1993; 194(1):314–331. [PubMed: 8386878]
- Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, Harada H, Downing JR. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. *Blood.* 1998; 91(9): 3134–3143. [PubMed: 9558367]

- Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell*. 1996; 84(2):321–330. [PubMed: 8565077]
- Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. *Blood*. 2008; 112(4):1392–1401. [PubMed: 18511808]
- Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. *Nat Med*. 2001; 7(4):444–451. [PubMed: 11283671]
- Park S, Chen W, Cierpicki T, Tonelli M, Cai X, Speck NA, Bushweller JH. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. *Blood*. 2009a; 113(15):3558–3567. [PubMed: 19204326]
- Park S, Speck NA, Bushweller JH. The role of CBFbeta in AML1-ETO's activity. *Blood*. 2009b; 114(13):2849–2850. [PubMed: 19779050]
- Park ST, Nolan GP, Sun XH. Growth inhibition and apoptosis due to restoration of E2A activity in T cell acute lymphoblastic leukemia cells. *J Exp Med*. 1999; 189(3):501–508. [PubMed: 9927512]
- Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. *Blood*. 2007; 109(10):4392–4398. [PubMed: 17284535]
- Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. *Oncogene*. 2004; 23(24):4255–4262. [PubMed: 15156181]
- Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. *Mol Cell Biol*. 1998; 18(7):3915–3925. [PubMed: 9632776]
- Plevin MJ, Zhang J, Guo C, Roeder RG, Ikura M. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain. *Proc Natl Acad Sci USA*. 2006; 103(27):10242–10247. [PubMed: 16803958]
- Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. *Leukemia*. 2012; 26(8):1829–1841. [PubMed: 22343733]
- Ptasinska A, Assi SA, Martinez-Soria N, Imperato MR, Piper J, Cauchy P, Pickin A, James SR, Hoogenkamp M, Williamson D, Wu M, Tenen DG, Ott S, Westhead DR, Cockerill PN, Heidenreich O, Bonifer C. Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal. *Cell Reports*. 2014; 8(6):1974–1988. [PubMed: 25242324]
- Quong MW, Romanow WJ, Murre C. E protein function in lymphocyte development. *Annu Rev Immunol*. 2002; 20(1):301–322. [PubMed: 11861605]
- Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. *Cell Reports*. 2014; 9(5):1841–1855. [PubMed: 25482556]
- Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. *Genes Dev*. 2015; 29(9):910–922. [PubMed: 25886910]
- Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. *J Biomed Biotechnol*. 2011; 2011:104631. [PubMed: 21629739]
- Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, Little MT, Tenen DG, Zhang DE. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. *Blood*. 2000; 96(6):2108–2115. [PubMed: 10979955]

- Rhoades KL, Hetherington CJ, Rowley JD, Hiebert SW, Nucifora G, Tenen DG, Zhang DE. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. *Proc Natl Acad Sci USA*. 1996; 93(21):11895–11900. [PubMed: 8876234]
- Rolland T, Ta an M, Charlotiaux B, Pevzner SJ, Zhong Q, Sahni N, Yi S, Lemmens I, Fontanillo C, Mosca R, Kamburov A, Ghiassian SD, Yang X, Ghamsari L, Balcha D, Begg BE, Braun P, Brehme M, Broly MP, Carvunis AR, Convery-Zupan D, Corominas R, Coulombe-Huntington J, Dann E, Dreze M, Dricot A, Fan C, Franzosa E, Gebreab F, Gutierrez BJ, Hardy MF, Jin M, Kang S, Kiros R, Lin GN, Luck K, MacWilliams A, Menche J, Murray RR, Palagi A, Poulin MM, Rambout X, Rasla J, Reichert P, Romero V, Ruysinck E, Sahalie JM, Scholz A, Shah AA, Sharma A, Shen Y, Spirohn K, Tam S, Tejada AO, Trigg SA, Twizere JC, Vega K, Walsh J, Cusick ME, Xia Y, Barabási AL, Iakoucheva LM, Aloy P, De Las Rivas J, Tavernier J, Calderwood MA, Hill DE, Hao T, Roth FP, Vidal M. A proteome-scale map of the human interactome network. *Cell*. 2014; 159(5):1212–1226. [PubMed: 25416956]
- Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G, Shurtleff SA, Pounds S, Cheng C, Ma J, Ribeiro RC, Rubnitz JE, Girtman K, Williams WK, Raimondi SC, Liang DC, Shih LY, Pui CH, Downing JR. Gene expression profiling of pediatric acute myelogenous leukemia. *Blood*. 2004; 104(12):3679–3687. [PubMed: 15226186]
- Roudaia L, Cheney MD, Manuylova E, Chen W, Morrow M, Park S, Lee CT, Kaur P, Williams O, Bushweller JH, Speck NA. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. *Blood*. 2009; 113(13):3070–3079. [PubMed: 19179469]
- Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. *Ann Genet*. 1973; 16(2):109–112. [PubMed: 4125056]
- Rowley JD. The role of chromosome translocations in leukemogenesis. *Semin Hematol*. 1999; 36(4 Suppl 7):59–72. [PubMed: 10595755]
- Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M. Towards a proteome-scale map of the human protein-protein interaction network. *Nature*. 2005; 437(7062):1173–1178. [PubMed: 16189514]
- Salat D, Liefke R, Wiedenmann J, Borggrefe T, Oswald F. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes. *Mol Cell Biol*. 2008; 28(10):3502–3512. [PubMed: 18332109]
- Samuel A, Stoner RD, Lo MC, Zhang DE. Tumor Suppressor RASSF2 Is Downregulated By The RUNX1-ETO Fusion Protein In t (8;21)+ Acute Myeloid Leukemia. *Blood*. 2013; 122:1268.
- Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. *J Clin Invest*. 2005; 115(8):2159–2168. [PubMed: 16025155]
- Scholl C, Gilliland DG, Fröhling S. Dereglulation of signaling pathways in acute myeloid leukemia. *Semin Oncol*. 2008; 35(4):336–345. [PubMed: 18692684]
- Schuh AH, Tipping AJ, Clark AJ, Hamlett I, Guyot B, Iborra FJ, Rodriguez P, Strouboulis J, Enver T, Vyas P, Porcher C. ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis. *Mol Cell Biol*. 2005; 25(23):10235–10250. [PubMed: 16287841]
- Schwartz R, Engel I, Fallahi-Sichani M, Petrie HT, Murre C. Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. *Proc Natl Acad Sci USA*. 2006; 103(26):9976–9981. [PubMed: 16782810]
- Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. *Wiley Interdiscip Rev Syst Biol Med*. 2010; 2(6):640–653. [PubMed: 20890962]
- Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, Yan H, Chen FF, Chen HM, Chen Z, Jin J, Chen SJ. Gene mutation patterns and their prognostic impact

in a cohort of 1185 patients with acute myeloid leukemia. *Blood*. 2011; 118(20):5593–5603. [PubMed: 21881046]

Shia WJ, Okumura AJ, Yan M, Sarkeshik A, Lo MC, Matsuura S, Komeno Y, Zhao X, Nimer SD, Yates JR 3rd, Zhang DE. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. *Blood*. 2012; 119(21):4953–4962. [PubMed: 22498736]

Shiina M, Hamada K, Inoue-Bungo T, Shimamura M, Uchiyama A, Baba S, Sato K, Yamamoto M, Ogata K. A novel allosteric mechanism on protein-DNA interactions underlying the phosphorylation-dependent regulation of Ets1 target gene expressions. *J Mol Biol*. 2015; 427(8): 1655–1669. [PubMed: 25083921]

Shrivastava T, Mino K, Babayeva ND, Baranovskaya OI, Rizzino A, Tahirov TH. Structural basis of Ets1 activation by Runx1. *Leukemia*. 2014; 28(10):2040–2048. [PubMed: 24646888]

Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, Fischle W, Melnick A, Patel DJ, Nimer SD, Roeder RG. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. *Nature*. 2013; 500(7460):93–97. [PubMed: 23812588]

Sykes DB, Kamps MP. Estrogen-dependent E2a/Pbx1 myeloid cell Lines exhibit conditional differentiation that can be arrested by other leukemic oncoproteins. *Blood*. 2001; 98:2308–2318. [PubMed: 11588024]

Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, Ishii S, Ogata K. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. *Cell*. 2001; 104(5):755–767. [PubMed: 11257229]

Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Nishida J, Shibata Y, Yazaki Y, Hirai H. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. *EMBO J*. 1995; 14(2): 341–350. [PubMed: 7530657]

Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. *Cell*. 2008; 133(4):612–626. [PubMed: 18485870]

Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, Darley RL. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. *Leukemia*. 2007; 21(12):2495–2505. [PubMed: 17898786]

Toyonaga K, Kikuchi H, Yamashita K, Nakayama M, Chijiwa K, Nakayama T. E2A participates in a fine control of pre-mature B-cell apoptosis mediated by B-cell receptor signaling via transcriptional regulation of survivin, IAP2 and caspase-8 genes. *FEBS J*. 2009; 276(5):1418–1428. [PubMed: 19187225]

Trombly DJ, Whitfield TW, Padmanabhan S, Gordon JA, Lian JB, van Wijnen AJ, Zaidi SK, Stein JL, Stein GS. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. *BMC Genomics*. 2015; 16(1):309. [PubMed: 25928846]

Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med*. 2004; 350(16):1617–1628. [PubMed: 15084694]

Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. *Proc Natl Acad Sci USA*. 1998; 95(18):10860–10865. [PubMed: 9724795]

Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, Nimer SD. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. *Science*. 2011a; 333(6043):765–769. [PubMed: 21764752]

Wang L, Man N, Sun XJ, Tan Y, Cao MG, Liu F, Hatlen M, Xu H, Huang G, Mattlin M, Mehta A, Rampersaud E, Benezra R, Nimer SD. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. *Blood*. 2015; 126(5):640–650. [PubMed: 26084673]

- Wang X, Truckses DM, Takada S, Matsumura T, Tanese N, Jacobson RH. Conserved region I of human coactivator TAF4 binds to a short hydrophobic motif present in transcriptional regulators. *Proc Natl Acad Sci USA*. 2007; 104(19):7839–7844. [PubMed: 17483474]
- Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R, Chen SJ. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. *Proc Natl Acad Sci USA*. 2011b; 108(6):2450–2455. [PubMed: 21262832]
- Warren AJ, Bravo J, Williams RL, Rabbitts TH. Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta. *EMBO J*. 2000; 19(12):3004–3015. [PubMed: 10856244]
- Wei H, Liu X, Xiong X, Wang Y, Rao Q, Wang M, Wang J. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain. *FEBS Lett*. 2008; 582(15):2167–2172. [PubMed: 18519037]
- Wei Y, Liu S, Lausen J, Woodrell C, Cho S, Biris N, Kobayashi N, Wei Y, Yokoyama S, Werner MH. A TAF4-homology domain from the corepressor ETO is a docking platform for positive and negative regulators of transcription. *Nat Struct Mol Biol*. 2007; 14(7):653–661. [PubMed: 17572682]
- Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. *Mol Cell Biol*. 1998; 18(1):322–333. [PubMed: 9418879]
- Wildonger J, Mann RS. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. *Development*. 2005; 132(10):2263–2272. [PubMed: 15829516]
- Wolford JK, Prochazka M. Structure and expression of the human MTG8/ETO gene. *Gene*. 1998; 212(1):103–109. [PubMed: 9661669]
- Wood JD, Nucifora FC Jr, Duan K, Zhang C, Wang J, Kim Y, Schilling G, Sacchi N, Liu JM, Ross CA. Atrophin-1, the dentatorubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. *J Cell Biol*. 2000; 150(5):939–948. [PubMed: 10973986]
- Yamaguchi Y, Kurokawa M, Imai Y, Izutsu K, Asai T, Ichikawa M, Yamamoto G, Nitta E, Yamagata T, Sasaki K, Mitani K, Ogawa S, Chiba S, Hirai H. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. *J Biol Chem*. 2004; 279(15):15630–15638. [PubMed: 14752096]
- Yan M, Ahn EY, Hiebert SW, Zhang DE. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. *Blood*. 2009; 113(4):883–886. [PubMed: 19036704]
- Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. *Proc Natl Acad Sci USA*. 2004; 101(49):17186–17191. [PubMed: 15569932]
- Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. *Nat Med*. 2006; 12(8):945–949. [PubMed: 16892037]
- Yan W, Young AZ, Soares VC, Kelley R, Benezra R, Zhuang Y. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. *Mol Cell Biol*. 1997; 17(12):7317–7327. [PubMed: 9372963]
- Yang G, Khalaf W, van de Locht L, Jansen JH, Gao M, Thompson MA, van der Reijden BA, Gutmann DH, Delwel R, Clapp DW, Hiebert SW. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. *Mol Cell Biol*. 2005; 25(14):5869–5879. [PubMed: 15988004]
- Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marín-Padilla M, Tenen DG, Speck NA, Zhang DE. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. *Nat Genet*. 1997; 15(3):303–306. [PubMed: 9054947]
- Yohe S. Molecular genetic markers in acute myeloid leukemia. *J Clin Med*. 2015; 4(3):460–478. [PubMed: 26239249]

- Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. *Proc Natl Acad Sci USA*. 2001; 98(18):10398–10403. [PubMed: 11526243]
- Zamir I, Zhang J, Lazar MA. Stoichiometric and steric principles governing repression by nuclear hormone receptors. *Genes Dev*. 1997; 11(7):835–846. [PubMed: 9106656]
- Zhang DE, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM, Hiebert SW, Tenen DG. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. *Mol Cell Biol*. 1996; 16(3):1231–1240. [PubMed: 8622667]
- Zhang J, Hug BA, Huang EY, Chen CW, Gelmetti V, Maccarana M, Minucci S, Pelicci PG, Lazar MA. Oligomerization of ETO is obligatory for corepressor interaction. *Mol Cell Biol*. 2001; 21(1):156–163. [PubMed: 11113190]
- Zhang J, Kalkum M, Chait BT, Roeder RG. The N-CoRHDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. *Mol Cell*. 2002; 9(3):611–623. [PubMed: 11931768]
- Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. E protein silencing by the leukemogenic AML1-ETO fusion protein. *Science*. 2004; 305(5688):1286–1289. [PubMed: 15333839]
- Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P, Reinberg D. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. *Cell*. 1997; 89(3):357–364. [PubMed: 9150135]
- Zhang YW, Yasui N, Ito K, Huang G, Fujii M, Hanai J, Nogami H, Ochi T, Miyazono K, Ito Y. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. *Proc Natl Acad Sci USA*. 2000; 97(19):10549–10554. [PubMed: 10962029]
- Zhao F, Vilardi A, Neely RJ, Choi JK. Promotion of cell cycle progression by basic helix-loop-helix E2A. *Mol Cell Biol*. 2001; 21(18):6346–6357. [PubMed: 11509675]
- Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Stolz C, Boehrer S, Gul H, Schneider O, Ottmann OG, Hoelzer D, Henschler R, Ruthardt M. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. *Blood*. 2004; 103(9):3535–3543. [PubMed: 14739224]
- Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW. Mouse models of human AML accurately predict chemotherapy response. *Genes Dev*. 2009; 23(7):877–889. [PubMed: 19339691]

Figure 1.

Schematic representations of domain organization of AML1-ETO, E2A-Pbx1, and the related wild-type proteins. RHD: runt homology domain. NHR1–4: nervy homology regions 1–4. NHR1 and NHR4 are also known as TAFH and MYND zinc fingers, respectively. AD1 and AD2: activation domains 1 and 2. DES: downstream ETO-interacting sequences, which includes a minimal binding sub-region named NHR2 binding (N2B) motif. HD: homeobox domain. bHLH: basic helix-loop-helix domain. The vertical dash lines depict the breakpoints during chromosomal translocation.

Figure 2.

Domains of AML1-ETO and their interacting proteins. Biochemical studies have identified an array of AML1-ETO-interacting proteins, many of which bind to the conserved RHD and NHR domains of AML1 and ETO, respectively. Proteins bound to RHD include: CBFβ (Meyers et al., 1995), AML1 (Li et al., 2015a), C/EBPα (Zhang et al., 1996), C/EBPβ (Tahirov et al., 2001), GATA1 (Elagib et al., 2003), Ets1 (Kim et al., 1999; Shrivastava et al., 2014; Shiina et al., 2015), PU.1 (Petrovick et al., 1998), MEF (Mao et al., 1999), LEF1 (Li et al., 2004), c-FOS/c-JUN (D'Alonzo et al., 2002), BSAP/PAX5 (Liebermann et al., 1999), SMAD3 (Jakubowiak et al., 2000), Sp1 (Wei et al., 2008). Some of the transcription factors may interact with AML1-ETO indirectly through the proximal binding sites on target DNA. Proteins bound to the ETO portion of the fusion protein include: Atrophin-1 (Wood et al., 2000), Dnmt1 (Liu et al., 2005), SHARP (Salat et al., 2008), JMJD1c (Chen et al., 2015), PLZF (Melnick et al., 2000), Bcl6 (Chevallier et al., 2004), HEB/E2A/LYL1/LMO2/Ldb1 (Sun et al., 2013), Gfi1 (McGhee et al., 2003), corepressors NCoR/SMRT/HDAC3, mSin3A/HDAC1/2 (Gelmetti et al., 1998; Lutterbach et al., 1998b; Wang et al., 1998; Amann et al., 2001; Hildebrand et al., 2001; Zhang et al., 2001), p300 (Wang et al., 2011a), HSP90 (Komori et al., 1999), ETO-2/MTGR1 (Kitabayashi et al., 1998; Liu et al., 2006), PKA (Riiα) (Fukuyama et al., 2001), and SON (Ahn et al., 2008). PRMT1 binds to AML1-ETO9a fragment (Shia et al., 2012). In addition to the reported binary interactions, proteome-scale mapping of the human interactome network further showed that ETO interacts with EPS8, MEOX2, STX11, ZMYM4, LPXN, HOMER3, SPRY2, MID2, GSE1, ABI3, TAF9B, WBP11, NECAB2, PRDM14, C19orf57, CPSF7, EFHC2, LZTS2, CREB3L1, SPERT, TRIM42, CCDC36, CEP170P1 (Rual et al., 2005; Rolland et al., 2014). Proteins that have been shown to involve direct interactions are highlighted in dark red.

Figure 3.

ETO and E-protein interactions. Schematic representations showing domain structures of ETO and E-proteins, along with the three binding interfaces: NHR1/AD1, NHR2/DES and NHR1/DES (Guo et al., 2009). DES harbors the minimal sub-region that shows binding to NHR2 (N2B).

Figure 4.

Differential involvement of ETO-corepressor/E-protein interactions in distinct leukemogenic pathways. (A) Alignment of PCET sequences from HEB, E2-2 and E2A. E2A-specific change is labeled with yellow stars. (B) In t(8;21) AML, strong AML1-ETO/E-protein (HEB or E2A) interactions facilitate transcriptional repression to promote leukemogenesis. (C) In t(1;19) ALL, due to E2A-specific amino-acid changes flanking the PCET motif, the binding affinity of E2A-Pbx1 to ETO-2/MTGR1 corepressors is reduced. As a result, E2A-Pbx1 is skewed toward recruiting p300/CBP HATs for gene activation.

Figure 5.

3D models of AML1-ETO and its complexes with binding partners. Available 3D structures of isolated AML1-ETO domains are shown by PyMOL and the structures were connected with dashed lines. RHD is colored in blue, its binding partner CBFβ in cyan, NHR1 in green, NHR2 in orange, NHR3 in hot pink, and NHR4 in red. For ETO binding partners, HEB peptides are in yellow, PKA (RIIα) in gray, and SMRT peptide in pale cyan. Note that NHR2 mediates tetramerization of AML1-ETO proteins (the other three NHR2 domains are in gray), thus bridging 4 copies of each interacting proteins. AML-ETO can also form hetero-oligomers with ETO family proteins (ETO-2, MTGR1).

Table 1

List of representative AML1-ETO target genes

Repression	Molecular/Biological functions	References
C/EBP α	Transcription factor, myeloid differentiation	Pabst et al., 2001
PIRIN	Transcription factor, myeloid differentiation	Licciulli et al., 2010
P14 (ARF)	Tumor suppressor	Linggi et al., 2002
Neurofibromatosis-1	Tumor suppressor	Yang et al., 2005
RASSF2	Tumor suppressor	Samuel A Stoner, 2013
CD45	Negative regulator of JAK/STAT signaling	Lo et al., 2012
Cathepsin G	Protease, AML1-ETO degradation	Jin et al., 2013
OGG1	DNA repair	Alcalay et al., 2003
Activation	Molecular/Biological functions	References
JUP(γ -Catenin)	Wnt/ β -Catenin signaling	Muller-Tidow et al., 2004; Zheng et al., 2004; Tonks et al., 2007
JAGGED1	Notch signaling	Alcalay et al., 2003
TRKA	Nerve Growth Factor receptor	Mulloy et al., 2005
ID1	Maintains HSC self-renewal	Jankovic et al., 2007
P21/WAF1	HSC self-renewal	Peterson et al., 2007
PONTIN	Cell cycle progression	Breig et al., 2014
BCL2	Apoptosis inhibitor	Klampfer et al., 1996
BCL-xl	Apoptosis inhibitor	Chou et al., 2012

Table 2

Reported 3D structures of AML1-ETO domains

Domain	Structure description	PDB number	References
RHD	RHD	1CO1, 1LJM, 1CMO	Berardi et al., 1999; Nagata et al., 1999; Bartfeld et al., 2002
	RHD + DNA	1HJC	Tahirov et al., 2001
	RHD + CBF β + C/EBP β + DNA	1IO4	Tahirov et al., 2001
	RHD + CBF β + DNA	1H9D	Bravo et al., 2001
	RHD + CBF β	1E50	Warren et al., 2000
NHR1(eTAFH)	NHR1	2H7B	Plevin et al., 2006
	NHR1 (F136Y)	2PP4	Wei et al., 2007
	NHR1 + HEB-PCET	2KNH	Park et al., 2009a
NHR2	NHR2	1WQ6	Liu et al., 2006
	NHR2 + HEB-N2B	4JOL	Sun et al., 2013
NHR3	NHR3 + PKA(RII α)	2KYG	Corpora et al., 2010
NHR4	NHR4	2OD1	Liu et al., 2007
	NHR4 + SMRT	2ODD	Liu et al., 2007
dTAFH	TAF4-TAFH	2P6V	Wang et al., 2007